Navigation Links
Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Date:12/11/2007

eceived at least one prior treatment for NHL. The trial is expected to enroll 300 patients.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and permit simplified administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of the final results of the RAPID clinical study of pixantrone to have the same or similar results to the interim analysis, or the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma or other cancers, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, co
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy versus Placebo for IBS Symptoms
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
8. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
11. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , MINNEAPOLIS, Nov. 20 /PRNewswire-FirstCa...unced results for its first quarter ended Septembe... per diluted share, on revenues of $3,263,000. Th...per diluted share, on revenues of $3,168,000 for t... the first quarter results, Biotel President and C...
(Date:11/20/2009)..., , PRINCETON, N.J., Nov. 20 /PRNewswire-... SNGX) (Soligenix or the Company), formerly known ... company, announced today that it has formed a con...nce RiVax(TM) and other rapidly acting vaccines. S...tional Institute of Allergy and Infectious Disease...
(Date:11/19/2009)..., , TAINAN, Taiwan, Nov. 19 /PRNewswi...of active pharmaceutical ingredients (APIs), annou...ent Compound Safety Certification from,SafeBridge(...inoPharm,s,competency and proficiency in the safe ...ts (APIs), and applies to specific laboratories an...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2InsiteResearch Market Momentum Continues to Accelerate 14033 1InsiteResearch Market Momentum Continues to Accelerate 14033 2InsiteResearch Market Momentum Continues to Accelerate 14033 3Implantable Defibrillators May Not Help Women With Heart Failure 57116 1Implantable Defibrillators May Not Help Women With Heart Failure 57116 2Implantable Defibrillators May Not Help Women With Heart Failure 57116 3Forest ecologist sees climate consequences 9921 1
(Date:11/21/2009)...e medical apparel company launches men,s lab coats... San Clemente, Calif. (PRWEB) November 21, 2009...pparel, today announced the launch of its men,s la...ading international trade fair for the medical ind...rates its men,s collection with three varying lab ...
(Date:11/21/2009)... Dental Group merges their practice with that of E... (PRWEB) November 21, 2009 -- The... David Gibson, Dr. Dean Cloutier, Dr. John Plachty...growing practice with that of esteemed colleague D... he wanted to retire from dentistry in order to co...
(Date:11/20/2009).../PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals C...reholders will be held on Monday, December 21, 200...val of two special resolutions. The first special ... all or substantially all of the assets of NUCRYST...sset purchase agreement dated November 10, 2009 am...
(Date:11/20/2009)...PRNewswire/ -- Following a recall by Unilever The ...ale Shedd,s Country Crock ® Side Dishes DELUX...® Side Dishes DELUXE Four Cheese Pasta due to...ing code dates and UPCs are affected: ,, Shedd... Broccoli Rice 21 oz, UPC 027400218316, Best By NO...
(Date:11/20/2009)...wire-USNewswire/ -- The American Dental Associatio...tration (FDA) to establish appropriate classificat...concern about the safety of whitening products tha...ofessional consultation or examination by a dentis...emically based tooth whitening or bleaching agents...
Breaking Medicine News(10 mins):Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:New Haven Dental Group Expands Their Vision 2Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2
... sustain a traumatic brain injury (TBI) each year,... long-term disability. It also is a major cause of...personnel. Despite the enormity of the pro...ped for traumatic brain injuries in over 30 years....
..., percutaneous coronary intervention (PCI, angiopl...rm risk of major cardiac events among heart attack...study. Cardiac ischemia is caused by insuf...e supply of oxygen to the heart muscle), but can b...
...aunched a comprehensive immunization programme acr... aimed at covering as many as 48 milllion people. ... the yellow fever, resurging in the region and is ... is a public-private partnership focused on increa...
... disability compensation for veterans, the U.S. De... how it evaluates former military personnel for se...SD) and determines the payment amounts they merit,...led inconsistencies in compensation levels awarded...
...ational Toxicology Program (NTP), has produced str...lent chromium (chromium 6) causes cancer when it ... chromium compounds are often used in electroplati...d developed malignant tumors upon administration o...
...relation between an extreme form of sleep disorder...of dementia or parkinsonism. Patients wit...Lewy body dementia, Parkinsons disease or multiple...researchers led by Bradley Boeve at Mayo Clinic. ...
Other Medicine News:Health News:Death and Disability from Brain Injury Reduced, Emory Researchers Report 2Health News:Angioplasty Reduces Long-term Cardiac Risk in Heart Patients With 'silent' Ischemia 2Health News:WHO Launches Yellow Fever Initiative for West Africa 2Health News:VA Should Revise Its Methods for Evaluating PTSD in Ex-military Personnel 2Health News:VA Should Revise Its Methods for Evaluating PTSD in Ex-military Personnel 3Health News:Researchers Find Link Between Sleep Disorder and Dementia 2
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: